Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oncolytic Virus (H101) Peritumoral Injection Combined With SBRT, Chemotherapy, Targeted Therapy, and Immunotherapy for Unresectable MSS/pMMR Colorectal Cancer Liver Metastases (CRLM)

NCT07381309 is registered in ClinicalTrials.gov with Jun Huang as lead sponsor.

NCT NCT07381309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07381309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oncolytic Virus (H101) Peritumoral Injection Combined With SBRT, Chemotherapy, Targeted Therapy, and Immunotherapy for Unresectable MSS/pMMR Colorectal Cancer Liver Metastases (CRLM)
Lead sponsor
Jun Huang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
February 1, 2029
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crc, liver metastasis colon cancer